Inclusion Criteria:

- Medically stable.

- Participants who could become pregnant: negative pregnancy test and contraception
for at least 28 days prior to Day 1 and for at least 90 days after the study
intervention administration.

- Have received ≥2 coronavirus disease 2019 (COVID-19) vaccines, with the last
COVID-19 vaccine administered >150 days prior to Day 1.

Exclusion Criteria:

- History of a diagnosis or condition that is clinically unstable or may affect
participant safety, assessment of study endpoints, assessment of immune response, or
adherence to study procedures.

- Tested positive for influenza by local health authority-approved testing methods
within 150 days prior to Day 1.

- History of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
within 150 days prior to Day 1.

- Received systemic immunosuppressive treatment, including long-acting biological
therapies that affect immune responses (eg, infliximab), within 180 days prior to
Day 1 or plans to do so during the study.

- Received or plans to receive any vaccine authorized or approved by a local health
agency within 28 days prior to Day 1 or plans to do so within 28 days post study
injection.

- Received a licensed seasonal influenza vaccine within 150 days prior to Day 1.

- Received a licensed/authorized COVID-19 vaccine within 150 days prior to Day 1.

- Received any investigational influenza vaccine, investigational COVID-19 vaccine, or
investigational combination vaccine for influenza and COVID-19 within 12 months
prior to Day 1.

- Participated in a clinical study with investigational treatment within 90 days prior
to Day 1 (Baseline).

Other protocol-defined inclusion/exclusion criteria may apply.